Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Suzhou City, China Clinical Trials

A listing of Suzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (110) clinical trials

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells

Phase

0.0 miles

Learn More »

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens ...

Phase

0.0 miles

Learn More »

KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.

Phase

0.0 miles

Learn More »

The Neuroprotective Effect of Remote Ischemic Conditioning in Aneurysm Coiling Therapy

The overall incidence of DWI positive for thromboembolic events following endovascular treatment of intracranial aneurysms is proximately 50%. Whether remote ischemic conditioning was safe and effective to reduce ischemic brain lesions on DWI after endovascular treatment of intracranial aneurysms is still unclear. The investigators' hypothesis is that remote ischemic conditioning ...

Phase

0.0 miles

Learn More »

Over-the-scope Clips and Standard Treatments in Endoscopic Control of Acute Bleeding From Non-variceal Upper GI Causes

Endoscopic therapy has improved outcomes to patients with acute non-variceal upper gastrointestinal bleeding. Acid suppression therapy as an adjunct to endoscopic therapy further reduces recurrent bleeding and interventions. There remains a small subgroup of patients who continue to bleed or re-bleed after initial endoscopic hemostasis. These patients are often elderly ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety of Balloon Guide Catheter in Mechanical Thrombectomy Patients

With mechanical thrombectomy now representing standard of care for treatment of acute ischemic stroke secondary to large vessel occlusion, identifying adjunctive techniques that result in improved outcomes for patients with LVO has become an issue of increasing importance. A number of retrospective studies have demonstrated that flow arrest during the ...

Phase

0.0 miles

Learn More »

Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir

Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China. The effective inhibition of HBV can partially stop or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV, and the ...

Phase

0.0 miles

Learn More »

Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV

Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of Liver cirrhosis in China. The effective inhibition of HBV can partially regress or reverse liver fibrosis in patients with chronic Hepatitis and liver cirrhosis due to HBV, however some ...

Phase

0.0 miles

Learn More »

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

The patients will receive infusion of CART cells targeting CD19 and CD22 to confirm the safety and efficacy of CD19/CD22 CART Cells in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Phase

0.0 miles

Learn More »

Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Lower Risk MDS

This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each, there is an up to 4 weeks screen period followed by a treatment period of 26 weeks and a 4 week follow up period.

Phase

0.0 miles

Learn More »